Table 1 Summary of target dosimetric indices for the 2-group plans.

From: Novel DCAT plans in stereotactic body radiotherapy for stage I/II centrally located non-small-cell lung cancer

Item

Planning Goal

DCAT

VMAT

P Value

ITV

D98% (Gy) > 48.0 Gy

54.19 (53.09–55.88)

55.48 (54.27–56.75)

0.201

D2% (Gy) < 77.0 Gy

62.60 (59.37–70.31)

69.07 (65.74–72.28)

0.001*

PTV

D98% (Gy) > 45.0 Gy

44.54 (42.12–46.48)

43.10 (41.76–45.33)

0.020*

D2% (Gy) < 77.0 Gy

62.60 (59.37–70.31)

69.07 (65.74–72.28)

0.001*

Dmean (Gy)

56.80 (54.97–59.81)

58.96 (57.15–59.87)

0.003*

CI < 1.5

1.15 (1.12–1.17)

1.13 (1.09–1.16)

0.048*

HI < 1.6

1.24 (1.19–1.38)

1.36 (1.29–1.39)

0.002*

D2cm (%)

52.18 (47.91–56.40)

50.68 (45.24–53.35)

< 0.001*

R50% < 7.5

4.86 (4.46–5.52)

4.52 (4.14–4.98)

< 0.001*

  1. Median (IQR) was reported. A statistically significant difference to the FFF-VMAT result is indicated by an asterisk (*). Abbreviations: ITV internal target volume, PTV planning target volume, CI conformity index, HI homogeneity index, DCAT dynamic conformal arc therapy, VMAT volumetric-modulated arc therapy, D2cm the maximum dose at any point ≥ 2 cm from the PTV in any direction, R50% the ratio of the volume encircled by the 50% prescription isodose line to the PTV volume.